

Diabetes Medications

Diabetes Care Coaching




OKAKI



2

Before We Begin ...



- Our goal is to create a safe space where all participants are comfortable to learn, share, ask questions
 - Everyone brings knowledge and expertise
 - I am always learning too
 - We won't record discussions, but will share monthly education videos
- The coaching sessions will focus on practical pieces of working in diabetes. For details, it is always best to reference the Diabetes Canada Clinical Practice Guidelines (guidelines.diabetes.ca)

3

What We Plan to Cover Today



- Diabetes medications
 - Classes
 - How they work
 - Supporting management
- (insulin to come next time ...)

4

Medications



Remember diabetes is a life-long and progressive disease

Diabetes impacts ALL PARTS of the body ... so treatment should too!



5

Helpful References



- Complete Diabetes Medications Table
 - <https://diabeteseducatorsocalgary.ca/medications/complete-medication-table.html>
- Okaki Meds Cheat Sheet
- Meds Poster
 - <https://www.diabete.qc.ca/wp-content/uploads/2024/05/114015-DQ25-TableauMedicaments-MAJ-EN-MR.pdf>


6




Biguanide

7

Metformin / Glumetza (extended release)








- Makes liver less leaky
- Improves insulin sensitivity
- Targets fasting BG



8

Biguanides – Metformin, Glumetza



	Decreased glucose output from liver, increased insulin sensitivity
A1C	1% reduction
\$	Affordable
	Weight neutral
	Negligible risk of hypoglycemia
	>45 full dose, 30-45 500-1000 mg, <30 use alternative agent
+	Reduction in myocardial infarction in overweight individuals
-	<ul style="list-style-type: none"> • GI side effects (important to take with food) • Vitamin B12 deficiency • Contraindicated in hepatic failure

9




Sulfonylureas

10

Diamicron (Gliclazide)  Diabeta (Glyburide)  Gluconorm (Repaglinide) 



- Helps beta cells release more insulin



11



Sulfonylureas – Gliclazide, Glyburide, Glimepiride



	Stimulates endogenous insulin secretion, dosed bid (MR available)
A1C	0.7-1.3% reduction
\$	Affordable
	+ 1.5-2.5 kg
	Gliclazide - minimal/moderate, Glyburide/glimepiride – moderate
	> 60 full dose, 30-60 caution, <30 use alternative agent
+	Rapid BG lowering response
-	Gliclazide preferred over glyburide/glimepiride due to lower risk of hypoglycemia, CV events, and mortality

12



Meglitinides - Repaglinide



	Stimulates endogenous insulin release, dosed with meals
A1C	0.7-1.1% reduction
\$	\$\$
	+ 0.7-1.8 kg
	Moderate risk of hypoglycemia
	> 30 full dose but greater risk of hypoglycemia, < 30 caution
+	Dosing flexibility
-	Contraindicated when co-administered with clopidogrel or with gemfibrozil

13




SGLT-2 Inhibitors

14

Jardiance  Forxiga  Invokana 
 (Empagliflozin Dapagliflozin Canagliflozin)






- Helps body get rid of extra sugar by peeing it out



15

SGLT-2 Inhibitors



	Inhibits SGLT-2 transport protein to prevent glucose reabsorption by the kidney (glucose excreted in urine)
A1C	0.4-0.7% reduction
	- 2-3 kg
	Negligible risk of hypoglycemia
+	Reduction in MACE and CV death, renal preservation, heart failure
-	Next slide

16

SGLT-2 Inhibitors



- Yeast infections or UTIs (more common in women)
- Hypotension
- Small increase in LDL-C
- Severe dehydration can be dangerous:
 - Rare cases of euglycemic diabetic ketoacidosis
 - Treatment should be withheld prior to major surgery or with serious illness or infections

17

SGLT-2 Inhibitors



When newly started on SGLT-2i:

- Review sick day management
- Check for low carbohydrate diets
- Emphasize importance of good hydration

18

SGLT-2 Inhibitors



Coverage:


- those who have been on Metformin and Gliclazide
- NIHB *“For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.”*

Combinations:

- Synjardy
- Invokamet
- Xigduo


19

DPP4i, GLP-1ra, GIPa



20

Understanding DPP-4, GLP-1, and GIP



21




DPP-4i Inhibitors

22

Januvia  Onglyza  Trajenta 
 (Sitagliptin Saxagliptin Linagliptin)







- Helps body make more insulin when eat carbohydrates



23

DPP-4i – Linagliptin, Saxagliptin, Sitagliptin








	Increases glucose dependent insulin release, inhibits glucagon release
A1C	0.5-0.7% reduction
\$	\$\$\$
	Weight neutral
	Negligible risk of hypoglycemia
	Lina > 15, Saxa adjust when 15-45, Sita adjust when 30-45, again 15-20
+	Typically well tolerated
-	<ul style="list-style-type: none"> • Rare cases of pancreatitis • Rare cases of severe joint pain • Caution with saxagliptin in participants with heart failure

24




GLP-1 Receptor Agonists

25

Ozempic (Semaglutide)	Victoza (Liraglutide)	Trulicity (Dulaglutide)	OKAKI Diabetes Virtual Care Clinic
			
<ul style="list-style-type: none">• Helps body release more insulin when eating carbs, slows digestion			
			

26



The diagram illustrates the physiological effects of GLP-1 agonists on various organs. At the top, a brain is marked with a yellow star and labeled "Increased satiety". Below it, a heart is marked with a yellow star and labeled "Cardioprotective". To the left of the heart, two muscular arms are shown, with the text "Decreased glucose output" positioned between them. Below the heart, a liver is marked with a yellow star. To the right of the liver, a stomach and pancreas are shown, with a yellow star on the pancreas labeled "Slowed digestion". Below the pancreas, two kidneys are shown, with a yellow star on the right kidney labeled "Glucose-dependant insulin production". The OKAKI logo is in the bottom left corner.

27

GLP-1 Receptor Agonists



Key points when starting:

- GI side effects and appetite
- Dosing and Injection technique
- Missed dose - take missed dose of Ozempic as soon as possible within 5 days after the missed dose
- Helpful website: <https://www.ozempic.com/how-to-take/ozempic-pen.html#ifu-video>

28

Rybelsus - Oral Semaglutide



- Works the same as subcutaneous semaglutide - increases glucose dependent insulin release, inhibits glucagon release, slows gastric emptying
- Both fasting and postprandial blood sugars targeted

Key points when starting:

- Take 30 mins before eating or drinking with water
- GI side effects
- Dosing

29

GLP-1 Receptor Agonists



Coverage:

- NIHB - Ozempic: *For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.*
- Provincial – Ozempic: *As add-on therapy for the treatment of Type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:*
 - *a sufficient trial (i.e. a minimum of 6 months) of metformin, AND*
 - *a sulfonylurea, AND*
 - *for whom insulin is not an option.*




Combinations

- Xultophy – Tresiba and Victoza
- Soliqua – Lantus and Adlyxin

30

GLP-1 Receptor Agonists



	Glucose-dependant insulin release, reduction in glucagon, slowed gastric emptying
A1C	1% reduction
	-1.6-3 kg
	Negligible risk of hypoglycemia
+	Primary CV prevention, secondary prevention of MACE
-	<ul style="list-style-type: none"> • GI side effects common (nausea, constipation, diarrhea) • Contraindicated with personal/family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) syndrome type 2 • Worsening of retinopathy (Sema) • Caution if history of pancreatitis

31



GLP-1 and GIP Agonist

32

Tirzepatide (Mounjaro)




- Helps body release more insulin when eating carbs, slows down digestion, makes body more sensitive to insulin
- Targets GLP-1 and GIP



33

Understanding DPP-4, GLP-1, and GIP



34



Others

35

AlphaglucoSIDase Inhibitors



- Acarbose
- Prevents starch breakdown and glucose absorption
- Postprandial blood sugars targeted





Key points when starting:

- Hypoglycemia treatment

36


AlphaglucoSIDase Inhibitors




	Inhibits pancreatic α -amylase and intestinal α -glucosidase
A1C	0.7-0.8% reduction
\$	\$\$
	Weight neutral
	Negligible risk of hypoglycemia
	<30, use alternative agent
+	n/a
-	<ul style="list-style-type: none"> • GI side effects common • Dosed tid • Must treat hypoglycemia with milk, glucose tabs, or honey

37

Thiazolidinediones (TZDs)








- Enhances insulin sensitivity in peripheral tissues and liver
- Fasting blood sugars targeted
- Pioglitazone (Actos)



38

Thiazolidinediones – pioglitazone, rosiglitazone



	Enhances insulin sensitivity in peripheral tissues and liver by activation of peroxisome proliferator activated receptor-activated receptor-gamma receptors
A1C	0.8-0.9% reduction
\$	\$\$\$
	+ 2.5-5 kg
	Negligible risk of hypoglycemia
	<60 use with caution
+	Mild increase in HDL-C
-	<ul style="list-style-type: none"> May induce edema and/or congestive heart failure Rare occurrence of macular edema Higher occurrence of fractures Pioglitazone not to be used with bladder cancer Controversy regarding MI risk for rosiglitazone

39



Talking About Meds in Patient Appointments

40

Medication Management



- Timing
- Consistency
- Managing/understanding side effects
- Teaching why/how the meds work

41

Sick Day Management



- S** • Sulfonylureas – diamicron, diabeta
- A** • ACE Inhibitors – ramipril, lisinopril, coversyl
- D** • Diuretics – lasix, hydrochlorothiazide
- M** • Metformin
- A** • ARBs - candesartan, losartan, telmisartan
- N** • NSAIDs – advil, motrin, aleve
- S** • SGLT-2 Inhibitors – jardiance, forxiga, onglyza


If unsure,
call 811

42



Medications in Practice

43



46

New Diagnosis and A1c > 1.5% above target

If no signs of metabolic decompensation:

- Metformin first

Why?

- Efficacy
- Safety
- Cost
- Weight neutral
- Minimal hypoglycemia risk
- Possible heart benefits

If not within target in 3 months, dose adjustments or additional agents

OKAKI Diabetes Virtual Care Clinic

47

Next step: how to choose?

- Patient preference and goals
- A1C
- Glucose patterns
- Medical history
- Potential for pregnancy
- Weight
- Hypoglycemia risk
- Renal function
- Contraindications
- Lifestyle
- Coverage**

48

Type 2 diabetes is a **progressive** disease, with **ongoing decline** in beta cell function.

It is normal to require additional agents to help manage glycemic control!

49

Wrapping Up...



- Do you have one or two takeaways that you can use in your work?
- Next Session: Tuesday, March 17th at 9:00 AM on Insulin